Floatz logo

Lenalidomide

Follicular Lymphoma

Sinocelltech Ltd.Small moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
65/ 100

Competitive context

196 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclosporin A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulfanum
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Lenalidomide is also rated in:

adult T-cell leukemia/lymphomaActive
BBB
Indicative · Phase 2
74 / 100
View asset →
plasma cell neoplasmActive
BBB
Indicative · Phase 3
72 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
BB
Indicative · Phase 2
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →